Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 5/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.35 |
| ▸ | SMOX | Q9NWM0 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23236800 | 0.88 | KDM1A (0.48) | KDM1APAOXSMOXALDH1A1TSHR | |
| SCHEMBL11595765 | 0.88 | KDM1A (0.43) | KDM1ATSHR | |
| SCHEMBL11595763 | 0.88 | KDM1A (0.43) | KDM1ATSHR | |
| SCHEMBL619432 | 0.87 | — | — | |
| SCHEMBL619431 | 0.87 | — | — | |
| SCHEMBL5884796 | 0.85 | TSHR (0.55) | KDM1ACYP2C19CYP1A2PAOXALDH1A1 | |
| SCHEMBL5884803 | 0.85 | TSHR (0.55) | KDM1ACYP2C19CYP1A2PAOXALDH1A1 | |
| SCHEMBL6900518 | 0.83 | — | — | |
| SCHEMBL184627 | 0.83 | — | — | |
| SCHEMBL22157514 | 0.83 | KDM1A (0.58) | KDM1AALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2552990-B1 | POLYURETHANE/POLYUREA SPRAY ELASTOMERS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2017-04-19 | — | — | EP | claimed |
| EP-2552990-A1 | POLYURETHANE/POLYUREA SPRAY ELASTOMERS | Dow Global Technologies LLC (US) | 2013-02-06 | — | — | EP | claimed |
| WO-2011123241-A1 | POLYURETHANE/POLYUREA SPRAY ELASTOMERS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2011-10-06 | — | — | WO | claimed |
| US-20240376246-A1 | ONE-POT PROCESS FOR THE PRODUCTION OF POLYCARBODIIMIDE CURED POLYMERS | BASF SE (DE) | 2024-11-14 | — | — | US | disclosed |
| EP-4402191-A1 | ONE-POT PROCESS FOR THE PRODUCTION OF POLYCARBODIIMIDE CURED POLYMERS | BASF SE (DE) | 2024-07-24 | — | — | EP | disclosed |
| WO-2023041443-A1 | ONE-POT PROCESS FOR THE PRODUCTION OF POLYCARBODIIMIDE CURED POLYMERS | BASF SE (DE) | 2023-03-23 | — | — | WO | disclosed |
| EP-2552990-B1 | POLYURETHANE/POLYUREA SPRAY ELASTOMERS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2017-04-19 | — | — | EP | disclosed |
| US-20140373918-A1 | PHOTOVOL TAlC MODULES AND METHODS OF MAKING THE SAME | PPG INDUSTRIES OHIO, INC. | 2014-12-25 | — | — | US | disclosed |
| EP-2552990-A1 | POLYURETHANE/POLYUREA SPRAY ELASTOMERS | Dow Global Technologies LLC (US) | 2013-02-06 | — | — | EP | disclosed |
| US-20130018147-A1 | POLYURETHANE/POLYUREA SPRAY ELASTOMERS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2013-01-17 | — | — | US | disclosed |
| US-8212078-B2 | Making chain extenders with slower cure rates; reacting a ketone and/or aldehyde with a primary amine in the presence of an acidic ion exchange resin and hydrogenation agent; making diimine same way but excluding hydrogenation agent; e.g. N,N'-di-5-nonyl-isophoronediamine | ALBEMARLE CORPORATION (US) | 2012-07-03 | — | — | US | disclosed |
| WO-2011123241-A1 | POLYURETHANE/POLYUREA SPRAY ELASTOMERS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2011-10-06 | — | — | WO | disclosed |
| US-7767858-B2 | Diimines and secondary diamines | ALBEMARLE CORPORATION (US) | 2010-08-03 | — | — | US | disclosed |
| EP-2143707-A2 | Secondary diamine | Albermarle Corporation (US) | 2010-01-13 | — | — | EP | disclosed |
| US-20080194788-A1 | Diimines and Secondary Diamines | ALBEMARLE CORPORATION (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080033210-A1 | DIIMINES AND SECONDARY DIAMINES | ALBEMARLE CORPORATION (US) | 2008-02-07 | — | — | US | disclosed |
| US-20080004406-A1 | DIIMINES AND SECONDARY DIAMINES | ALBEMARLE CORPORATION (US) | 2008-01-03 | — | — | US | disclosed |
| US-7288677-B2 | Diimines and secondary diamines | ALBEMARLE CORPORATION (US) | 2007-10-30 | — | — | US | disclosed |
| US-20070073030-A1 | Chain Extenders | ALBEMARLE CORPORATION (US) | 2007-03-29 | — | — | US | disclosed |
| US-20060217567-A1 | Diimines and secondary diamines | ALBEMARLE CORPORATION | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004406-A1 | DIIMINES AND SECONDARY DIAMINES | DDT, DDC, AOC1 | KDM1A 673/4885CYP2C19 802/4885MEN1 556/4885 |
| US-20080033210-A1 | DIIMINES AND SECONDARY DIAMINES | DDT, DDC, AOC1 | KDM1A 673/4885CYP2C19 802/4885MEN1 556/4885 |
| US-20080194788-A1 | Diimines and Secondary Diamines | DDT, DDC, AOC1 | KDM1A 580/4885CYP2C19 1125/4885MEN1 593/4885 |
| US-20060217567-A1 | Diimines and secondary diamines | DDT, DDC, AOC1 | KDM1A 673/4885CYP2C19 802/4885MEN1 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.